Why the study?
What is the rate of thromboembolic complications in patients receiving vitamin K antagonists treated with prothrombin complex concentrates for bleeding or before urgent surgery?
What is the rate of thromboembolic complications in patients receiving vitamin K antagonists treated with prothrombin complex concentrates for bleeding or before urgent surgery?
The use of prothrombin complex concentrates for rapid VKA reversal is associated with a low but quantifiable risk of thromboembolic complications (1.4%).
No takes yet. Share an insight, caveat, or question.
Quantifies low thromboembolic risk with PCCs for VKA reversal; reinforces safety profile but leaves optimal factor selection open.
Marchesi et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: